Improving support for our patients across Australia.
3 February 2020
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for patients nationally.
The new MPA/MIA agreement will focus on the introduction of a Tele Health Nurse Pilot Program to provide better access of services for melanoma patients; increasing the capacity and expertise of MPA’s Peer to Peer volunteer facilitators and volunteer support staff; enhancing face to face support groups within NSW and integration of these into MPA’s national support network; and joint involvement in events including patient information sessions and MIA’s national Melanoma March campaign.
With survival rates continuing to improve, the need for this collaboration to strengthen the support services available to our patients and families, is, thankfully, even greater. ’ Victoria Beedle, CEO of Melanoma Patients Australia
Melanoma patients and their families throughout the Riverina region will also benefit from strengthened and sustained melanoma services with the merger of Amie St Clair and Melanoma Institute Australia. It will provide immediate benefits by doubling the level of services provided to melanoma patients in the Riverina, including increased capacity of the free melanoma nursing services, the establishment of clinical trials in Wagga Wagga, opportunities for melanoma patients within the region to contribute to MIA research, and melanoma education opportunities – both professional (GPs/Clinics) and communitybased through the SunSafe Student Ambassador program.
‘Our shared vision is zero deaths from melanoma, no matter where you live, and this is a fantastic opportunity to enhance the effective delivery of treatment and support services to melanoma patients in this region.’ Annette St Clair, Co-founder of Amie St Clair Melanoma Trust
MIA is also delighted to be merging with melanomaWA, providing increased resources dedicated to reducing the impact of melanoma in Western Australia.
The two highly respected organisations will be working together on a regional and national level regarding awareness, education, support, and research.’ Mr Martin Slabbert, Chairman melanomaWA
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.